Publications

Detailed Information

Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice

DC Field Value Language
dc.contributor.authorJeong, Jae Min-
dc.contributor.authorHong, Mee Kyung-
dc.contributor.authorChang, Young Soo-
dc.contributor.authorLee, Yun-Sang-
dc.contributor.authorKim, Young Joo-
dc.contributor.authorCheon, Gi Jeong-
dc.contributor.authorLee, Dong Soo-
dc.contributor.authorChung, June-Key-
dc.contributor.authorLee, Myung Chul-
dc.date.accessioned2010-06-22T04:53:36Z-
dc.date.available2010-06-22T04:53:36Z-
dc.date.issued2008-04-17-
dc.identifier.citationJ Nucl Med. 2008;49(5):830-836en
dc.identifier.issn0161-5505 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18413379-
dc.identifier.urihttp://jnm.snmjournals.org/cgi/reprint/49/5/830.pdf-
dc.identifier.urihttps://hdl.handle.net/10371/67753-
dc.description.abstractArg-Gly-Asp (RGD) derivatives have been labeled with various radioisotopes for the imaging of angiogenesis in ischemic tissue, in which alpha(v)beta(3) integrin plays an important role. In this study, cyclic Arg-Gly-Asp-D-Tyr-Lys [c(RGDyK)] was conjugated with 2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (SCN-Bz-NOTA) and then labeled with (68)Ga. The labeled RGD so produced was subjected to an in vitro binding assay and in vivo biodistribution and PET studies. METHODS: A mixture of SCN-Bz-NOTA (660 nmol) and c(RGDyK) (600 nmol) in 0.1 M sodium carbonate buffer (pH 9.5) was allowed to react for 20 h at room temperature in the dark for thiourea bond formation. The conjugate obtained was purified by semipreparative high-performance liquid chromatography (HPLC). The purified c(RGDyK)-SCN-Bz-NOTA (NOTA-RGD) was then labeled with (68)Ga from a (68)Ge/(68)Ga generator and purified by semipreparative HPLC. A competitive binding assay for c(RGDyK) and NOTA-RGD was performed with (125)I-c(RGDyK) as a radioligand and alpha(v)beta(3) integrin-coated plates as a solid phase. (68)Ga-NOTA-RGD (0.222 MBq/100 microL) was injected, through a tail vein, into mice with hind limb ischemia and into mice bearing human colon cancer SNU-C4 xenografts. Biodistribution and imaging studies were performed at 1 and 2 h after injection. RESULTS: The labeling of NOTA-RGD with (68)Ga was straightforward. The K(i) values of c(RGDyK) and NOTA-RGD were 1.3 and 1.9 nM, respectively. In the biodistribution study, the mean +/- SD uptake of (68)Ga-NOTA-RGD by ischemic muscles was 1.6+/-0.2 percentage injected dose per gram (%ID/g); this uptake was significantly blocked by cold c(RGDyK) to 0.6+/-0.3 %ID/g (P<0.01). Tumor uptake was 5.1+/-1.0 %ID/g, and the tumor-to-blood ratio was 10.3+/-4.8. Small-animal PET revealed rapid excretion through the urine and high levels of tumor and kidney uptake. CONCLUSION: Stable (68)Ga-NOTA-RGD was obtained in a straightforward manner at a high yield and showed a high affinity for alpha(v)beta(3) integrin, specific uptake by angiogenic muscles, a high level of uptake by tumors, and rapid renal excretion. (68)Ga-NOTA-RGD was found to be a promising radioligand for the imaging of angiogenesis.en
dc.language.isoenen
dc.publisherThe Society of Nuclear Medicine Incen
dc.subjectAnimalsen
dc.subjectAnoxia/radionuclide imagingen
dc.subjectFeasibility Studiesen
dc.subjectGallium Radioisotopesen
dc.subjectHeterocyclic Compounds/chemical synthesis/*chemistry/*diagnostic useen
dc.subjectHindlimb/blood supply/pathologyen
dc.subjectHumansen
dc.subjectIschemia/radionuclide imagingen
dc.subjectIsothiocyanates/chemical synthesis/*chemistry/*diagnostic useen
dc.subjectMaleen
dc.subjectMiceen
dc.subjectNeovascularization, Pathologic/*radionuclide imagingen
dc.subjectOligopeptides/*chemistryen
dc.subjectPositron-Emission Tomography/*methodsen
dc.subjectStaining and Labelingen
dc.subjectTransplantation, Heterologousen
dc.titlePreparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in miceen
dc.typeArticleen
dc.contributor.AlternativeAuthor정재민-
dc.contributor.AlternativeAuthor홍미경-
dc.contributor.AlternativeAuthor장영수-
dc.contributor.AlternativeAuthor이윤상-
dc.contributor.AlternativeAuthor김영주-
dc.contributor.AlternativeAuthor천기정-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor이명철-
dc.identifier.doi10.2967/jnumed.107.047423-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share